It is possible that SGT-53 treatment downregulates tumor expression of Tgfb, which is a key regulator of the signaling pathways that initiate and maintain FoxP3 expression and the suppressive function in CD4+CD25− precursors [42]. The gene discussed is CD4; the disease is neoplasm.